Despite winning an alopecia areata approval for its drug Leqselvi in July, Sun Pharma will have to wait a while longer to ...
Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...
Incyte reported strong Q3 revenue growth, mainly driven by Jakafi and Opzelura, with a 24% increase year-over-year. Find out ...
On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year, beating ...
With Jakafi's patent cliff looming, Incyte looks to 2025 launches to bulk up revenue by decade's end
Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no ...
Shares of Incyte (NASDAQ:INCY) jumped 8% after the company reported better-than-expected Q3 revenue and raised sales guidance ...
Incyte (Nasdaq: INCY) announced today that it will present at the following investor conferences during the month of November ...
Incyte delivered robust third-quarter revenue growth, surpassing expectations, despite increased operational costs.
Shares of Incyte Corp. INCY inched 0.11% higher to $65.24 Thursday, on what proved to be an all-around mixed trading session ...
Incyte (INCY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Andrew Berens ...
In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Incyte (INCY – Research Report), with a price target of ...
Shares of Incyte Co. (NASDAQ:INCY – Get Free Report) have been assigned an average recommendation of “Hold” from the twenty-one brokerages that are covering the company, Marketbeat.com reports. One ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback